Tissue Regenix Group (FRA:LSW) OCF Margin %: -1.46% (As of Jun. 2025)

What is Tissue Regenix Group OCF Margin %?

Tissue Regenix Group FRA:LSW 10 OCF Margin % is -1.46% as of Jun. 2025. GuruFocus rates FRA:LSW with a GF Score™ of 10/100 and a GF Value™ of €0.84. The stock has 5 warning signs investors should review.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Tissue Regenix Group's Cash Flow from Operations for the six months ended in Jun. 2025 was €-0.18 Mil. Tissue Regenix Group's Revenue for the six months ended in Jun. 2025 was €11.96 Mil. Therefore, Tissue Regenix Group's OCF Margin % for the quarter that ended in Jun. 2025 was -1.46%.

As of today, Tissue Regenix Group's current OCF Yield % is -8.36%.

The historical rank and industry rank for Tissue Regenix Group's OCF Margin % or its related term are showing as below:

FRA:LSW' s OCF Margin % Range Over the Past 10 Years
Min: -8267.69 Med: -44.02 Max: 3.95
Current: -1.65

During the past 13 years, the highest OCF Margin % of Tissue Regenix Group was 3.95%. The lowest was -8267.69%. And the median was -44.02%.

FRA:LSW's OCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -66.52 vs FRA:LSW: -1.65

Tissue Regenix Group OCF Margin % Related Terms

Tissue Regenix Group OCF Margin % Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group OCF Margin % Chart

Tissue Regenix Group Annual Data

Trend

Jan15

Jan16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

OCF Margin %

Get a 7-Day Free Trial

-36.76

-15.07

-5.29

3.95

-5.71

Tissue Regenix Group Semi-Annual Data
	Jul15	Jan16	Jul16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25
OCF Margin %	Get a 7-Day Free Trial															-4.96	14.24	-9.41	-1.82	-1.46

FRA:LSW vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Tissue Regenix Group's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's OCF Margin % falls into.

Save Embed

10GF Score

Tissue Regenix Group PLC FRA:LSW

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tissue Regenix Group OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Tissue Regenix Group's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-1.561	/	27.357
	=	-5.71 %

Tissue Regenix Group's OCF Margin for the quarter that ended in Jun. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Jun. 2025 )	/	Revenue (Q: Jun. 2025 )
	=	-0.175	/	11.961
	=	-1.46 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -1.46% mean?

Tissue Regenix Group (FRA:LSW) has a OCF Margin % of -1.46% as of Jun. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tissue Regenix Group and its competitors.

Is Tissue Regenix Group's OCF Margin % too high?

Tissue Regenix Group's current OCF Margin % is -1.46%. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Tissue Regenix Group's OCF Margin % compare to VRTX and REGN?

Tissue Regenix Group's OCF Margin % of -1.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current OCF Margin % is -1.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tissue Regenix Group stock overvalued right now?

Tissue Regenix Group (FRA:LSW) has a current OCF Margin % of -1.46%. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current OCF Margin % is -1.46%. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current OCF Margin % is -1.46% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?

Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued. The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.

Key valuation signals for FRA:LSW:

OCF Margin %: -1.46%
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tissue Regenix Group Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:CRTX AQSE:INC LSE:NFX LSE:TCF LSE:CIZ LSE:FUM LSE:BSFA LSE:ROQ LSE:VAL LSE:OPTI VRTX REGN ALNY ASX:CSL XBRU:ARGX XBRU:UCB XKRX:207940 INSM ONC XKRX:068270

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY

Website https://www.tissueregenix.com

Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.

10GF Score

Get the complete analysis for FRA:LSW

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07

Price

€0.84

GF Value

View FRA:LSW Analysis

See OCF Margin % data for all stocks →